Pharmaroth Net Income Applicable To Common Shares from 2010 to 2026

ROTH Stock  USD 0.0001  0.00  0.00%   
Pharmaroth Labs' Net Loss is increasing with slightly volatile movements from year to year. Net Loss is predicted to flatten to about -86.5 K. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-82.4 K
Current Value
-86.5 K
Quarterly Volatility
126.9 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Pharmaroth Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharmaroth Labs' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 154.1 K or Total Revenue of 219.2 K, as well as many indicators such as Price To Sales Ratio of 10.56, Dividend Yield of 0.0 or Days Sales Outstanding of 193. Pharmaroth financial statements analysis is a perfect complement when working with Pharmaroth Labs Valuation or Volatility modules.
  
Build AI portfolio with Pharmaroth Stock
Check out the analysis of Pharmaroth Labs Correlation against competitors.
For more detail on how to invest in Pharmaroth Stock please use our How to Invest in Pharmaroth Labs guide.
The Net Income Applicable To Common Shares trend for Pharmaroth Labs offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Pharmaroth Labs is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Pharmaroth Labs' Net Income Applicable To Common Shares Growth Pattern

Below is the plot of the Net Income Applicable To Common Shares of Pharmaroth Labs over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Pharmaroth Labs' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharmaroth Labs' overall financial position and show how it may be relating to other accounts over time.
Net Income Applicable To Common Shares10 Years Trend
Slightly volatile
   Net Income Applicable To Common Shares   
       Timeline  

Pharmaroth Net Income Applicable To Common Shares Regression Statistics

Arithmetic Mean(159,772)
Coefficient Of Variation(79.42)
Mean Deviation107,532
Median(91,521)
Standard Deviation126,898
Sample Variance16.1B
Range359.3K
R-Value0.59
Mean Square Error11.3B
R-Squared0.34
Significance0.01
Slope14,727
Total Sum of Squares257.6B

Pharmaroth Net Income Applicable To Common Shares History

2026-86.5 K
2025-82.4 K
2016-91.5 K
2015-232.8 K
2011-370 K
2010-10.7 K

About Pharmaroth Labs Financial Statements

Investors use fundamental indicators, such as Pharmaroth Labs' Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although Pharmaroth Labs' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Loss-82.4 K-86.5 K

Currently Active Assets on Macroaxis

When determining whether Pharmaroth Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pharmaroth Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmaroth Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmaroth Labs Stock:
Check out the analysis of Pharmaroth Labs Correlation against competitors.
For more detail on how to invest in Pharmaroth Stock please use our How to Invest in Pharmaroth Labs guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is there potential for Biotechnology market expansion? Will Pharmaroth introduce new products? Factors like these will boost the valuation of Pharmaroth Labs. Anticipated expansion of Pharmaroth directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Pharmaroth Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
0.002
The market value of Pharmaroth Labs is measured differently than its book value, which is the value of Pharmaroth that is recorded on the company's balance sheet. Investors also form their own opinion of Pharmaroth Labs' value that differs from its market value or its book value, called intrinsic value, which is Pharmaroth Labs' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Pharmaroth Labs' market value can be influenced by many factors that don't directly affect Pharmaroth Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Pharmaroth Labs' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pharmaroth Labs should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Pharmaroth Labs' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.